Formulary Search

You are here : Home > Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Return to the search options.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Inflammatory bowel disease (Mesalazine - Inflammatory bowel disease)

Records returned : 38 (on 29 May 2025 at 13:28:37). Return to search results for ' Inflammatory bowel disease '.

Show Icon and Status Keys Hide Icon and Status Keys

Icon Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off-label use. Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

Cancer Drugs Fund

ICB

Treatment commissioned by the ICB

BlueTeq form to be completed

NICE

Link to the NICE website

Low carbon device

Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across the Surrey Heartlands Integrated Care System

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

See narrative

See narrative - may be applied in instances where a traffic light status has not yet been agreed but an entry to the formulary has been made to clarify interim arrangements.

Drug

Indication

Status

Restrictions/Comments

Formulary Status

Links

1. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Green (see narrative)

Formulations :

Gastro-resistant tablets

Restrictions / Comments:

Important

Preferred

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Prescribe by brand.: Octasa or Salofalk gastro resistant tablets (or Salofalk granules) are 1st line for new patients Asacol tablets are non-formulary

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

2. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Green (see narrative)

Formulations :

Suppositories

Restrictions / Comments:

Important

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Prescribe by brand: Octasa, Salofalk, Pentasa

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

3. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Green (see narrative)

Formulations :

Modified release tablets

Restrictions / Comments:

Important

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Mezevant XL - Reserve for patients with a high pill burden.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

4. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Green (see narrative)

Formulations :

Granules (slow release)
Modified release tablets

Restrictions / Comments:

Important

Preferred

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Prescribe by brand: Salofalk granules are a 1st-line option for new patients. Pentasa modified-release tablets and granules for patients who require upper GI release.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

5. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Green (see narrative)

Formulations :

Enema
Foam enema

Restrictions / Comments:

Important

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Prescribe by brand: Pentasa / Salofalk enema

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

6. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Non Formulary

Formulations :

Gastro-resistant tablets

Restrictions / Comments:

Important

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Asacol 400mg gastro resitsant tablets have been discontinued. The 800mg tablets are non-formulary.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

7. Budesonide

Drug:

Budesonide

Indication :

Inflammatory bowel disease

Status :

Green

Formulations :

Foam enema

Restrictions / Comments:

Important

Steroid safety considerations

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

20. Budesonide

Drug:

Budesonide

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Modified release capsules

Restrictions / Comments:

Important

Steroid safety considerations

3mg MR capsules - gastroenterology team only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

38. Budesonide

Drug:

Budesonide

Indication :

Inflammatory bowel disease

Status :

See narrative

Formulations :

Suppositories

Restrictions / Comments:

Important

Steroid safety considerations

Not assessed for formulary status. Applications for formulary entry via APC.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

NFD2

8. Prednisolone

Drug:

Prednisolone

Indication :

Inflammatory bowel disease

Status :

Green

Formulations :

Tablets

Restrictions / Comments:

Important

Tablets can be dispersed for immediate administration.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

9. Prednisolone

Drug:

Prednisolone

Indication :

Inflammatory bowel disease

Status :

Green

Formulations :

Soluble tablets

Restrictions / Comments:

Important

Paediatrics only at SASH. Paediatrics and oncology at ASPH

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

10. Prednisolone

Drug:

Prednisolone

Indication :

Inflammatory bowel disease

Status :

Green

Formulations :

Oral solution

Restrictions / Comments:

Important

Paediatric doses and NG/NJ tube only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

36. Prednisolone

Drug:

Prednisolone

Indication :

Inflammatory bowel disease

Status :

Non Formulary

Formulations :

Foam enema

Restrictions / Comments:

Important

Budesonide rectal foam is preferred. Steroid safety considerations

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

NFD1

37. Prednisolone

Drug:

Prednisolone

Indication :

Inflammatory bowel disease

Status :

Non Formulary

Formulations :

Gastro-resistant tablets

Restrictions / Comments:

Important

Enteric coated tablets - non-formulary

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

NFD1

11. Allopurinol

Drug:

Allopurinol

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Tablets

Restrictions / Comments:

Important

Off-label use in combination with azathioprine and mercaptopurine

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

12. Azathioprine

Drug:

Azathioprine

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Oral suspension
Tablets

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

13.

Drug:

Indication :

Inflammatory bowel disease

Status :

Amber

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

14. Mercaptopurine

Drug:

Mercaptopurine

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Oral suspension
Tablets

Restrictions / Comments:

Important

Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

15. Methotrexate

Drug:

Methotrexate

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Injection
Tablets

Restrictions / Comments:

Important

DO NOT prescribe or supply 10mg tablets. WEEKLY dose frequency. Advise patients to carry the patient alert card / book

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

16. Sulfasalazine

Drug:

Sulfasalazine

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Oral suspension
Tablets

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

17. Sulfasalazine

Drug:

Sulfasalazine

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Gastro-resistant tablets

Restrictions / Comments:

Important

Enteric coated tablets are significantly more expensive. Reserve for patients unable to tolerate plain tablets.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

18. Sulfasalazine

Drug:

Sulfasalazine

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Suppositories

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

19. Adalimumab

Drug:

Adalimumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Subcutaneous injection (sc)

Restrictions / Comments:

Important

For UC & CD. Adults only. Prescribe by brand.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

21. Ciclosporin

Drug:

Ciclosporin

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Capsules
Intravenous infusion

Restrictions / Comments:

Important

Ulcerative colitis only. Prescribe by brand

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

22. Ciclosporin

Drug:

Ciclosporin

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Oral solution

Restrictions / Comments:

Important

Ulcerative colitis only. Prescribe by brand

Ulcerative colitis only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

23. Etrasimod

Drug:

Etrasimod

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Tablets

Restrictions / Comments:

Important

Ulcerative colitis only

NICE guidance applies to Ulcerative Colitis patients only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

24. Filgotinib

Drug:

Filgotinib

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Tablets

Restrictions / Comments:

Important

Ulcerative colitis - adults only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

25. Golimumab

Drug:

Golimumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Subcutaneous injection (sc)

Restrictions / Comments:

Important

Ulcerative Colitis in Adults only. Prescribe by brand.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

26. Infliximab

Drug:

Infliximab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Intravenous infusion
Subcutaneous injection (sc)

Restrictions / Comments:

Important

For UC & CD. Prescribe by brand

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

27. Mirikizumab

Drug:

Mirikizumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Intravenous infusion
Subcutaneous injection (sc)

Restrictions / Comments:

Important

Ulcerative Colitis - adults only.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

28. Ozanimod

Drug:

Ozanimod

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Capsules

Restrictions / Comments:

Important

Ulcerative Colitis - adults only.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

29. Risankizumab

Drug:

Risankizumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Intravenous infusion
Subcutaneous injection (sc)

Restrictions / Comments:

Important

For UC & CD. Adults only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

30. Tofacitinib

Drug:

Tofacitinib

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Tablets

Restrictions / Comments:

Important

Ulcerative colitis - adults only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

31. Upadacitinib

Drug:

Upadacitinib

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Modified release tablets

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

32. Ustekinumab

Drug:

Ustekinumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Intravenous infusion
Subcutaneous injection (sc)

Restrictions / Comments:

Important

Adults only.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

33. Vedolizumab

Drug:

Vedolizumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Infusion
Subcutaneous injection (sc)

Restrictions / Comments:

Important

Not 1st line. Only in patients where steroids and/or TNF inhibitor not effective / appropriate

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

34. Balsalazide sodium

Drug:

Balsalazide sodium

Indication :

Inflammatory bowel disease

Status :

Non Formulary

Formulations :

Not Specified

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

35. Olsalazine sodium

Drug:

Olsalazine sodium

Indication :

Inflammatory bowel disease

Status :

Non Formulary

Formulations :

Capsules
Tablets

Restrictions / Comments:

Important

Licensed in mild ulcerative colitis

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC